[Treatment of autoimmune hepatic diseases].
The immunosuppresive drugs, primarily glucocorticosteroids, serve as the basis for the pathogenetic treatment of autoimmune diseases of the liver. In autoimmune hepatitis, immunosuppressive therapy induces and maintains persistent remission in most patients while in primary biliary cirrhosis and primary sclerosing cholangitis, its capacities are substantially limited. Ursodeoxycholic acid is used as the basic drug in predominantly occurring intrahepatic cholestasis. The treatment of cross autoimmune syndromes generally requires the choice of a combination of drugs.
Bueverov
A O
AO
D000328:Adult; D001327:Autoimmune Diseases / Q000175:diagnosis / Q000188:drug therapy*; D002648:Child; D002756:Cholagogues and Choleretics / Q000008:administration & dosage / Q000627:therapeutic use; D015209:Cholangitis, Sclerosing / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology; D002780:Cholestasis, Intrahepatic / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology; D004359:Drug Therapy, Combination; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use; D019693:Hepatitis, Autoimmune / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D008105:Liver Cirrhosis, Biliary / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology; D008107:Liver Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D011379:Prognosis; D012307:Risk Factors; D013577:Syndrome; D013997:Time Factors; D014580:Ursodeoxycholic Acid / Q000008:administration & dosage / Q000627:therapeutic use
D002756:Cholagogues and Choleretics; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D014580:Ursodeoxycholic Acid